Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: May 11, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Predicting Clinical Response to Benralizumab Using CT Imaging: Prognostic BenraliScan Study.

Arnaud Bourdin¹, Marie Felicia Beclin², Pascal Chanez³

¹Department of Respiratory Medicine, Centre Hospitalier Universitaire de Montpellier, Montpellier, France; PhyMedExp, Institut National de la Santé et de la Recherche Médicale, CNRS, Montpellier, France; Department of Thoracic Imaging, Department of Radiology, Arnaud de Villeneuve Hospital, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.

|May 9, 2026

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Switching Biologics in Severe Asthma: Cautionary Lessons from NIMBLE.

American journal of respiratory and critical care medicine·2026

Same author

Severe asthma and remission prospects in Europe (SHARP): insights from a multicentre observational study based on the European Severe Asthma Registry.

The Lancet. Respiratory medicine·2026

Same author

Gender differences in psychoactive substances causing emergency department admissions in children and adolescents.

Clinical toxicology (Philadelphia, Pa.)·2026

Same author

The AIM4 Next Step study: Comparing inhaled corticosteroid dose escalation to dupilumab in patients with uncontrolled asthma and type 2 inflammation.

The journal of allergy and clinical immunology. Global·2026

Same author

Educational Intervention on Environmentally Responsible Inhaler Prescribing Among French General Practitioners: Pilot Pre-Post Study.

JMIR formative research·2026

Same author

Complex interplay between disease and aerobic exercise training on vascular function in an exacerbated emphysema rat model.

Journal of applied physiology (Bethesda, Md. : 1985)·2026

Same journal

How I Do It: De-escalation of Prostacyclin-Based Therapy in Patients Treated With Sotatercept.

Chest·2026

Same journal

Eisenmenger Syndrome: The Pulmonology Perspective.

Chest·2026

Same journal

Phenotyping of pulmonary arterial hypertension associated with congenital heart disease using latent class analysis: insights from a national prospective registry.

Chest·2026

Same journal

Septic Shock and GLP-1 Analogue Association in Real World - A Propensity Score Matched Analysis.

Chest·2026

Same journal

PREVALENCE AND RISK FACTORS OF PRESERVED RATIO IMPAIRED SPIROMETRY (PRISm) IN PEOPLE WITH HIV AND MATCHED POPULATION CONTROLS.

Chest·2026

Same journal

How I Do It: Counseling Patients About Outdoor Exercise During Air Pollution Events.

Chest·2026

See all related articles

Summary

This summary is machine-generated.

Computed tomography (CT)-derived metrics, specifically PRM^SAD and sinus score, show promise in predicting benralizumab response in severe eosinophilic asthma (SEA) patients. These CT measures may aid in personalized treatment strategies for asthma management.

Area of Science:

Pulmonology and Respiratory Medicine
Medical Imaging
Pharmacology

Background:

Benralizumab is effective for eosinophilic asthma but response varies.
Baseline computed tomography (CT)-derived metrics were investigated for predicting treatment outcomes.
Severe eosinophilic asthma (SEA) is characterized by high eosinophil counts (>300/mm³).

Purpose of the Study:

To determine if baseline CT-derived measures can predict clinical response to benralizumab in SEA patients.
To assess the prognostic value of CT metrics for exacerbation reduction, lung function, and symptom control at 52 weeks.
To compare the predictive power of CT metrics against blood eosinophil levels.

Main Methods:

A prospective, open-label, two-center study involving 59 SEA patients initiating benralizumab.

Keywords:

ROC curve antibodies area under curve asthma benralizumab biologic therapy biomarkers eosinophilia eosinophils humans lung monoclonal mucus prospective studies tomography

More Related Videos

Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer

Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer

Published on: May 20, 2016

Related Experiment Videos

Last Updated: May 11, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer

Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer

Published on: May 20, 2016

Baseline CT scans were analyzed for metrics including PRM^SAD, UCSF-mucus plugging, and Lund-Mackay sinus score.

Primary outcome: ≥50% reduction in exacerbation rates; Secondary outcome: composite clinical score (≥2 of exacerbation reduction, FEV1 increase, ACQ-5 improvement).

Main Results:

47 patients completed the study; 42/47 (89%) achieved ≥50% exacerbation reduction.
35/47 (74%) patients met the composite secondary outcome.
PRM^SAD (AUC=0.693) and sinus score (AUC=0.714) were significant predictors of response, outperforming blood eosinophil count (AUC=0.630).

Conclusions:

CT-derived metrics (PRM^SAD, sinus score) are associated with benralizumab response in SEA patients.
These CT measures may serve as valuable biomarkers for predicting treatment success.
CT phenotyping could enhance precision management of SEA, warranting further validation.